RecruitingNot ApplicableNCT06687564
Role of ACTG2 Variants in Smooth Muscle Determination and Function in Pediatric Intestinal Pseudo-obstruction.
Sponsor
University Hospital, Grenoble
Enrollment
4 participants
Start Date
Feb 4, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
The primary objective of this study is to describe the transcriptional impact of R178, R257, R40 or A136 variants of the ACTG2 gene on iPS differentiation mechanisms up to organoids derived from PIPO patient samples versus those derived from control / WT patients (generation of IPS from cultured cell lines), at different stages of their experimental ex vivo development.
Eligibility
Min Age: 4 Years
Inclusion Criteria9
- PIPO Population:
- Minor or adult patient ≥ 4 years of age
- Patient with PIPO before age 18
- Male or female
- Patient with PIPO meeting at least 2 of the ESPGHAN criteria (Thapar et al 2018) and carrying the R178, R257, R40 or A136 mutation of the ACTG2 gene.
- Patient whose assent has been obtained and whose legal guardians have given their written informed consent
- Patient affiliated to the French Social Security system or benefiting from an equivalent plan
- WT population:
- \- iPS cell lines MS573 or WT8288 or 202CT or SD378M, from the Nantes University Hospital biological collection and generated from samples from control patients without POIC who have consented to donate their samples.
Exclusion Criteria3
- PIPO population :
- Patients with a history of radiotherapy treatment
- Patient with lymphocyte lineage damage
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
PROCEDUREBiopsy
A skin biopsy and a blood sample will be taken to culture the iPS cells and intestinal organoids.
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06687564